Public Health Link om the Chief Medical Officer for Wales

Distribution:	As Appendix 2		
From:	Chief Pharmaceutical Officer, Andrew Evans		
Date:	5 April 2019		
Reference:	CEM/CPhA/2019/8		
Category:	Class 4 - For Information		
Title:	DRUG ALERT CLASS 4, SUN PHARMACEUTICAL INDUSTRIES EUROPE BV -ZOLEDRONIC ACID 5MG SOLUTION FOR INFUSION		
Hospital pharmad			
For Information:	See Annex 2 – Distribution List		
What is this about:	Full details are set out below.		
Why has it been sent:	For your information, action and to pass on to colleagues.		

Issue:

Some packs from one particular batch of Zoledronic Acid 5mg solution for infusion (Pharmaceutical Industries Europe BV) contain the wrong Patient Information Leaflet (PIL).

Action as attached pdf.

Appendix 1

To: Chief Executives of Health Boards and NHS Trusts

To: Medical Directors of Health Boards

To: Nurse Directors Health Boards

To: Directors of Public Health

To: Hospital Principals and Chief Pharmacists to action as per alert

To: NHS Wales Shared Services Partnership to forward to:

HB Prescribing Advisers

Independent/Private clinics and Hospitals and Hospices throughout Wales





DRUG ALERT

CLASS 4 MEDICINES DEFECT INFORMATION

Caution in Use Distribute to Hospital Pharmacy Level

Date: 04 April 2019

EL (19)A/08

Our Ref: MDR 51-03/19

Dear Healthcare Professional.

Sun Pharmaceutical Industries Europe BV

Zoledronic acid 5mg solution for infusion

PL 31750/0054

Batch Number	Expiry Date	Pack Size	First Distributed
JKT1576A	30/04/2020	1 x 100ml	12 Oct 2018

Brief description of the problem

Ranbaxy (UK) Ltd a Sun Pharmaceutical Company, has informed us that some packs from the above batch contain a Patient Information Leaflet (PIL) for Temozolomide 180mg Capsules.

Advice for healthcare professionals

When dispensing the above batch, please check the PIL. If the pack contains the wrong PIL, please remove it and provide a copy of the correct PIL. This can be downloaded via the following link: https://www.medicines.org.uk/emc/product/5242/pil

Further Information

For any enquiries, please contact Ranbaxy / Sun Pharmaceuticals customer services team: Email Cserv.uk@sunpharma.com; Tel 020 8848 5050

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter.

Yours faithfully

Defective Medicines Report Centre 10 South Colonnade Canary Wharf London E14 4PU Telephone +44 (0)20 3080 6574